PFKM and colorectal carcinoma: In parallel experiments, cetuximab activity was evaluated by a spheroid‐formation assay (Fig. 7D and Fig. S7) and for its capacity to inhibit lactate production and PFK1 activity in RAS‐wild‐type CRC spheres (Fig. 7E).